scholarly article | Q13442814 |
P819 | ADS bibcode | 2014PLoSO...996849V |
P356 | DOI | 10.1371/JOURNAL.PONE.0096849 |
P932 | PMC publication ID | 4048166 |
P698 | PubMed publication ID | 24905984 |
P5875 | ResearchGate publication ID | 262930400 |
P50 | author | M.Luz Calle | Q61758563 |
Esther W de Bekker-Grob | Q91539297 | ||
Ellen C Zwarthoff | Q91657944 | ||
Ferran Algaba | Q114329108 | ||
Ulrika Segersten | Q114335480 | ||
Mirari Márquez | Q114441075 | ||
Willemien Beukers | Q114441115 | ||
Nuria Malats | Q28360608 | ||
Ewout W. Steyerberg | Q37828851 | ||
Lars Dyrskjøt | Q39568973 | ||
Francisco X Real | Q54394817 | ||
Per-Uno Malmström | Q58469511 | ||
P2093 | author name string | Torben F Ørntoft | |
Moniek M Vedder | |||
Manoils Kogevinas | |||
P2860 | cites work | Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer | Q63966334 |
Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases | Q80315009 | ||
External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer | Q83053056 | ||
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables | Q84215941 | ||
Bladder cancer: validating the EORTC risk tables in BCG-treated patients | Q84773139 | ||
Assessing the generalizability of prognostic information | Q33540894 | ||
Prediction models in urology: are they any good, and how would we know anyway? | Q33940100 | ||
Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer | Q34320071 | ||
External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients | Q34320813 | ||
Decision curve analysis: a novel method for evaluating prediction models | Q34581068 | ||
The 2004 WHO classification of bladder tumors: a summary and commentary | Q36111995 | ||
Statistical consideration for clinical biomarker research in bladder cancer | Q36124883 | ||
Assessing the performance of prediction models: a framework for traditional and novel measures | Q36617895 | ||
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. | Q37182161 | ||
Multiple imputation in health-care databases: an overview and some applications | Q37767543 | ||
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. | Q38119345 | ||
Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review | Q38166720 | ||
A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome | Q40196067 | ||
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee | Q40831782 | ||
Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α. | Q44822041 | ||
Bladder cancer: epidemiology, staging and grading, and diagnosis. | Q45247416 | ||
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. | Q45816848 | ||
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. | Q51953901 | ||
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. | Q53177490 | ||
The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. | Q54772321 | ||
A dynamic model for the risk of bladder cancer progression | Q61732905 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | e96849 | |
P577 | publication date | 2014-06-06 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours | |
P478 | volume | 9 |
Q40609183 | Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden |
Q58759191 | EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification |
Q91230892 | External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system |
Q28395447 | Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype |
Q49988036 | HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer. |
Q87618943 | Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy? |
Q35762587 | Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer |
Q38424934 | Novel biomarkers to predict response and prognosis in localized bladder cancer |
Q38400923 | Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer |
Q36040421 | Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models |
Q58764414 | Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8 T cells |
Q64262696 | Prediction tools in non-muscle invasive bladder cancer |
Q36862682 | Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. |
Q42370597 | Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer. |
Q38621223 | Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma |
Q90678306 | Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis |
Search more.